This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Investing in the Age of Longevity: Silver Economy Stocks in Focus
by Urmimala Biswas
AbbVie, Amgen, Stryker and Dexcom are tapping into the booming silver economy with new therapies, tech and acquisitions aimed at aging populations.
Why Is DexCom (DXCM) Down 7% Since Last Earnings Report?
by Zacks Equity Research
DexCom (DXCM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
DexCom Expands Access and Innovation While Balancing Headwinds
by Zacks Equity Research
DXCM grows on type 2 access, Stelo adoption, and new sensor launches, but faces margin pressures, competition and leadership transition.
Trinity Biotech's Redesigned CGM Sensor Favored by New Clinical Data
by Zacks Equity Research
TRIB's needle-free CGM+ sensor shows accurate 15-day results with no calibration, slashing costs and boosting access.
Abbott's Q2 Diabetes Care Sales Rise 19.6%: What's Backing It?
by Sridatri Sarkar
ABT's Diabetes Care sales surge 19.6% in Q2, fueled by strong U.S. demand and new OTC approvals for its CGM systems.
DexCom Stock Falls Despite Q2 Earnings Beat & 2025 Sales View Raise
by Zacks Equity Research
DXCM beats on Q2 earnings and raises 2025 sales guidance, but shares dip as margin pressure dampens investor enthusiasm.
Compared to Estimates, DexCom (DXCM) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for DexCom (DXCM) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
DexCom (DXCM) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
DexCom (DXCM) delivered earnings and revenue surprises of +6.67% and +3.06%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
DexCom (DXCM) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
by Zacks Equity Research
Besides Wall Street's top-and-bottom-line estimates for DexCom (DXCM), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.
Will DXCM Q2 Earnings Reflect U.S. Coverage Expansion & Stelo Impact?
by Zacks Equity Research
DexCom Q2 results are likely to reflect strong growth on the back of coverage by two large PBMs and Stelo traction, driving momentum and market expansion in 2025.
Are Medical Stocks Lagging DexCom (DXCM) This Year?
by Zacks Equity Research
Here is how DexCom (DXCM) and Amarin (AMRN) have performed compared to their sector so far this year.
DexCom (DXCM) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
DexCom (DXCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how DexCom (DXCM) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.
3 Reasons Growth Investors Will Love DexCom (DXCM)
by Zacks Equity Research
DexCom (DXCM) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Here's Why DexCom (DXCM) is a Strong Momentum Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why DexCom (DXCM) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
DXCM's Access Gains and Operational Strength Offset Margin Pressures
by Zacks Equity Research
DXCM rides on record patient growth and T2D access gains, but margin pressure and FDA scrutiny cloud the outlook.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RSPH
Profit From the Silver Tsunami: Must-Watch Senior Care & Aging Stocks
by Urmimala Biswas
BSX, ABBV, AMGN and DXCM are tapping into the aging boom with cutting-edge tech, chronic care drugs and senior-focused innovations.
QGEN Stock Might Gain Following New Partnership With ID Solutions
by Zacks Equity Research
QGEN teams up with ID Solutions to boost QIAcuity's reach in oncology dPCR assays, aiming to strengthen its cancer research leadership.
Walgreens Opens New Micro-Fulfillment Center in Brooklyn Park
by Zacks Equity Research
WBA expands micro-fulfillment with a new facility in Brooklyn Park, MN. This will support nearly 200 Walgreens stores across the Midwest.
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?
by Zacks Equity Research
Sector ETF report for RSPH
Neogen Stock Gains Following Strategic Alliance With Syngenta
by Zacks Equity Research
NEOG inks a new strategic licensing and supply agreement with Syngenta to market and sell the latter's Talon-G and Talon Weatherblok XT rodenticides in the United States and Canada.
Here's Why You Should Add DexCom Stock to Your Portfolio Now
by Zacks Equity Research
DXCM continues to raise investor optimism due to its strong product portfolio.